LENZ Therapeutics, Inc. (LENZ) 10-Year Financial Performance & Capital Metrics

LENZ • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Show more

Revenue $0
EBITDA -$59M +19.1%
Net Income -$50M +28.9%
EPS (Diluted) -2.34 +84.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -89.37%
ROIC -152.14%
Debt/Equity 0.01
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.17%

EPS CAGR

10Y-

5Y-

3Y-

TTM70.2%

ROCE

10Y Avg-459.33%

5Y Avg-459.33%

3Y Avg-82.1%

Latest-45.65%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	15M	0	0
Revenue Growth %	-	-	-	-	-1%	-
Cost of Goods Sold+	0	121K	734K	0	0	58K
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	-121K	-734K	15M	0	-58K
Gross Margin %	-	-	-	1%	-	-
Gross Profit Growth %	-	-	-5.07%	21.44%	-1%	-
Operating Expenses+	29K	13.38M	59.71M	25.48M	72.43M	58.55M
OpEx % of Revenue	-	-	-	1.7%	-	-
Selling, General & Admin	29K	4.26M	21.78M	4.36M	12.93M	28.75M
SG&A % of Revenue	-	-	-	0.29%	-	-
Research & Development	0	9.12M	37.93M	21.13M	59.5M	29.8M
R&D % of Revenue	-	-	-	1.41%	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-29K	-13.5M	-60.44M	-10.48M	-72.43M	-58.61M
Operating Margin %	-	-	-	-0.7%	-	-
Operating Income Growth %	-	-464.52%	-3.48%	0.83%	-5.91%	0.19%
EBITDA+	142.86K	-13.38M	-59.71M	-10.47M	-72.41M	-58.55M
EBITDA Margin %	-	-	-	-0.7%	-	-
EBITDA Growth %	-	-94.65%	-3.46%	0.82%	-5.91%	0.19%
D&A (Non-Cash Add-back)	171.86K	121K	734K	8K	15K	58K
EBIT	-29K	-68.33M	-70.76M	-10.48M	-72.43M	-49.77M
Net Interest Income+	-80K	-40K	0	0	2.19M	8.55M
Interest Income	0	0	0	0	2.19M	8.55M
Interest Expense	80K	40K	0	0	0	0
Other Income/Expense	-80K	-54.87M	-10.32M	19K	2.28M	8.84M
Pretax Income+	-109K	-68.37M	-70.76M	-10.46M	-70.15M	-49.77M
Pretax Margin %	-	-	-	-0.7%	-	-
Income Tax+	0	0	0	347K	-179K	1K
Effective Tax Rate %	1%	1%	1%	1.03%	1%	1%
Net Income+	-109K	-68.37M	-70.76M	-10.81M	-69.97M	-49.77M
Net Margin %	-	-	-	-0.72%	-	-
Net Income Growth %	-	-626.28%	-0.03%	0.85%	-5.47%	0.29%
Net Income (Continuing)	-109K	-68.37M	-70.76M	-10.81M	-69.97M	-49.77M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-8.24	-8.54	-12.89	-15.30	-2.34
EPS Growth %	-	-628.01%	-0.04%	-0.51%	-0.19%	0.85%
EPS (Basic)	-0.01	-8.24	-8.54	-12.89	-15.30	-2.34
Diluted Shares Outstanding	8.3M	8.3M	8.29M	7.84M	8.15M	21.28M
Basic Shares Outstanding	8.3M	8.3M	8.29M	7.84M	8.15M	21.28M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6K	21.1M	18.32M	46.64M	67.24M	211.92M
Cash & Short-Term Investments	6K	19.82M	18.31M	44.44M	65.79M	209.03M
Cash Only	6K	19.82M	18.31M	44.44M	35.14M	20.16M
Short-Term Investments	0	0	0	0	30.65M	188.87M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	1.29M	16K	2.2M	1.45M	114K
Total Non-Current Assets+	0	1.46M	12K	310K	3.13M	3.39M
Property, Plant & Equipment	0	1.46M	10K	279K	372K	1.99M
Fixed Asset Turnover	-	-	-	53.76x	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	2K	31K	2.76M	1.4M
Total Assets+	6K	22.56M	18.34M	46.95M	70.38M	215.3M
Asset Turnover	-	-	-	0.32x	-	-
Asset Growth %	-	3759.67%	-0.19%	1.56%	0.5%	2.06%
Total Current Liabilities+	2.22M	32.05M	1.25M	9.5M	18.51M	10.41M
Accounts Payable	0	630K	460K	4.75M	5.71M	4.26M
Days Payables Outstanding	-	1.9K	228.75	-	-	26.79K
Short-Term Debt	2.21M	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	19K	30.95M	0	0	0	0
Current Ratio	0.00x	0.66x	14.62x	4.91x	3.63x	20.36x
Quick Ratio	0.00x	0.66x	14.62x	4.91x	3.63x	20.36x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	316K	31.3M	61.62M	144.57M	814K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	147K	192K	814K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	316K	31.3M	61.47M	144.38M	0
Total Liabilities	2.22M	32.36M	32.55M	71.12M	163.09M	11.22M
Total Debt+	2.21M	0	0	250K	329K	1.38M
Net Debt	2.2M	-19.82M	-18.31M	-44.19M	-34.81M	-18.78M
Debt / Equity	-	-	-	-	-	0.01x
Debt / EBITDA	15.43x	-	-	-	-	-
Net Debt / EBITDA	15.39x	-	-	-	-	-
Interest Coverage	-0.36x	-337.50x	-	-	-	-
Total Equity+	-2.22M	-9.8M	-14.21M	-24.17M	-92.71M	204.08M
Equity Growth %	-	-3.42%	-0.45%	-0.7%	-2.84%	3.2%
Book Value per Share	-0.27	-1.18	-1.72	-3.08	-11.38	9.59
Total Shareholders' Equity	-2.22M	-9.8M	-14.21M	-24.17M	-92.71M	204.08M
Common Stock	0	0	1K	10K	10K	1K
Retained Earnings	-2.22M	-70.59M	-14.47M	-25.28M	-95.25M	-145.01M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	6K	196K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19K	-8.72M	-52.85M	-87.98M	-60.38M	-59.39M
Operating CF Margin %	-	-	-	-5.87%	-	-
Operating CF Growth %	-	-458%	-5.06%	-0.66%	0.31%	0.02%
Net Income	-109K	-68.37M	-70.76M	-101.05M	-69.97M	-49.77M
Depreciation & Amortization	0	121K	734K	8.35M	15K	58K
Stock-Based Compensation	0	0	0	0	1.34M	6.37M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	80K	57.82M	19.67M	11.93M	-1.18M	-2.95M
Working Capital Changes	10K	1.71M	-2.5M	-7.21M	9.41M	-13.09M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	-12K	594K	1.82M	194K	856K	-4.28M
Cash from Investing+	0	-1.54M	-5.74M	-241.86M	-29.62M	-154.48M
Capital Expenditures	0	-1.54M	-5.74M	-6.59M	-30K	-468K
CapEx % of Revenue	-	-	-	0.44%	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	0	30.08M	417.47M	597K	80.7M	199M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	306K	0	-2.28M	119.49M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-19K	-10.27M	-58.59M	-94.57M	-60.41M	-59.86M
FCF Margin %	-	-	-	-6.3%	-	-
FCF Growth %	-	-539.32%	-4.71%	-0.61%	0.36%	0.01%
FCF per Share	-0.00	-1.24	-7.07	-12.06	-7.42	-2.81
FCF Conversion (FCF/Net Income)	0.17x	0.13x	0.75x	8.14x	0.86x	1.19x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-	-	-89.37%
Return on Invested Capital (ROIC)	-	-	-	-	-	-152.14%
Gross Margin	-	-	-	100%	-	-
Net Margin	-	-	-	-72.07%	-	-
Debt / Equity	-	-	-	-	-	0.01x
Interest Coverage	-0.36x	-337.50x	-	-	-	-
FCF Conversion	0.17x	0.13x	0.75x	8.14x	0.86x	1.19x
Revenue Growth	-	-	-	-	-100%	-

Frequently Asked Questions

Growth & Financials

LENZ Therapeutics, Inc. (LENZ) reported $17.5M in revenue for fiscal year 2024.

LENZ Therapeutics, Inc. (LENZ) grew revenue by 0.0% over the past year. Growth has been modest.

LENZ Therapeutics, Inc. (LENZ) reported a net loss of $58.9M for fiscal year 2024.

Dividend & Returns

LENZ Therapeutics, Inc. (LENZ) has a return on equity (ROE) of -89.4%. Negative ROE indicates the company is unprofitable.

LENZ Therapeutics, Inc. (LENZ) had negative free cash flow of $46.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener